Radiation proctitis is inflammation and damage to the lining of the rectum caused by radiation therapy. It most commonly develops after treatment for prostate, cervical, or rectal cancers, since the rectum sits close to these organs and absorbs some of the radiation directed at them. The condition comes in two forms: an acute version that appears during or shortly after treatment, and a chronic version that can surface months or even years later.
Acute vs. Chronic Radiation Proctitis
The acute form typically shows up during the course of radiation treatment or in the weeks immediately following it. Symptoms tend to be relatively mild: diarrhea, a frequent or urgent need to use the bathroom, and light rectal bleeding. For most people, acute radiation proctitis resolves on its own once radiation treatment ends, though it can take several weeks to fully settle down.
Chronic radiation proctitis is the more concerning form. It can develop anywhere from three months to several years after radiation therapy finishes. Rather than simple inflammation, the chronic version involves deeper changes to rectal tissue. Blood vessels become fragile and prone to bleeding, scar tissue builds up, and the rectal wall can stiffen and lose its normal flexibility. These changes are progressive, meaning the damage accumulates over time rather than healing the way an acute injury would.
What the Symptoms Feel Like
The hallmark symptom of radiation proctitis is rectal bleeding, which can range from occasional spotting on toilet paper to more significant blood loss that leads to anemia over time. Beyond bleeding, people commonly experience tenesmus, the persistent feeling that you need to have a bowel movement even when the rectum is empty. This sensation can be uncomfortable and frustrating.
Other symptoms include rectal urgency (needing to reach a bathroom quickly), increased frequency of bowel movements, mucus discharge, and cramping or pain during bowel movements. In more severe or advanced cases, chronic radiation proctitis can lead to narrowing of the rectum (strictures), which makes it difficult to pass stool, or the formation of abnormal connections between the rectum and nearby organs like the bladder or vagina. If the radiation field included the anal sphincter, some people also experience fecal incontinence.
How Severity Is Graded
Doctors use a standardized five-point scale to classify how serious radiation proctitis is. Grade 1 means mild rectal discomfort that doesn’t require treatment. Grade 2 involves symptoms like rectal bleeding or mucus discharge that interfere with daily activities and need medical attention. Grade 3 means severe symptoms, including fecal urgency or incontinence, that limit your ability to care for yourself. Grade 4 is life-threatening and requires emergency intervention. Grade 5 is death, which is extremely rare but reflects that the most severe complications, like perforation or uncontrolled bleeding, can be dangerous.
Treatment for Mild to Moderate Cases
For chronic radiation proctitis with ongoing bleeding, medicated enemas are often the first approach. Sucralfate enemas, which coat and protect the damaged rectal lining, have shown strong results. In one controlled trial, 94% of patients treated with sucralfate enemas experienced clinical improvement, compared to 53% of those given steroid enemas. A longer-term study found that 88% of patients had negligible or complete cessation of bleeding after 16 weeks of sucralfate therapy, and 71% of those followed for a median of nearly four years had no recurrent bleeding.
Results do vary. A more recent study using sucralfate paste enemas found that after a six-week course, about 32% of patients had complete resolution of all symptoms (bleeding, urgency, frequency, and cramping) while another 41% had partial improvement. So while sucralfate helps the majority of people, it doesn’t work for everyone, and some patients need additional or different treatment.
Procedures for Persistent Bleeding
When enemas aren’t enough to control bleeding, a procedure called argon plasma coagulation (APC) is commonly used. This is done during a colonoscopy or sigmoidoscopy: a probe delivers a jet of argon gas and electrical energy to cauterize the fragile, bleeding blood vessels on the rectal surface. Most people need multiple sessions spaced a few weeks apart.
APC controls bleeding completely in about 69% of patients when measured at least a year after the final treatment session, with effectiveness rates across studies ranging from 50% to 100% depending on how strictly success is defined. The procedure does carry risks. About 13% of patients in one study experienced serious complications, including the formation of rectal fistulas (abnormal openings between the rectum and surrounding tissue). This is why APC is generally reserved for bleeding that hasn’t responded to more conservative treatment.
Hyperbaric Oxygen Therapy
For cases that don’t respond to enemas or cauterization, hyperbaric oxygen therapy is another option. You sit in a pressurized chamber and breathe pure oxygen for about 90 minutes per session. The high-oxygen environment promotes the growth of new, healthy blood vessels in the damaged rectal tissue and helps repair the underlying injury rather than just treating the surface symptoms.
The commitment is significant: most people need 30 to 40 sessions, sometimes up to 60, delivered daily over several weeks. But the results are encouraging. Symptoms improve in roughly 85% to 95% of patients, and about half achieve complete resolution of bleeding and urgency. The benefits tend to last at least 6 to 12 months after treatment ends. The therapy is well tolerated, though the time commitment and limited availability of hyperbaric chambers can be practical barriers.
Prevention During Prostate Radiation
For men undergoing radiation therapy for prostate cancer, a hydrogel spacer can significantly reduce the risk of radiation proctitis. This is a gel injected between the prostate and the rectum before radiation begins, physically pushing the rectum away from the highest-dose radiation zone. The spacer dissolves on its own over several months.
The dose reduction to the rectum is substantial. In a pooled analysis of six studies, the volume of rectum receiving high-dose radiation dropped from 10.4% to 3.5% with a spacer in place. In a Phase 3 clinical trial, 97% of patients with a spacer achieved meaningful reductions in rectal radiation exposure. The clinical payoff becomes clearer over time: at three years, the rate of significant rectal toxicity was 0% in patients who had a spacer compared to 6% in those who did not, a 77% relative reduction in a pooled analysis of four studies. If you’re planning prostate radiation, asking about a hydrogel spacer is worth the conversation.